ALTRAZEAL Press Releases

01/12/2015

Addison, Texas, January 12, 2015; ULURU Inc. (OTCQB: ULUR) today provided an update on recent developments. Initial shipments, which will be reflected in the fourth quarter results, have been made for Germany and Saudi Arabia.
Read More

11/04/2014

Addison, Texas, November 4, 2014; ULURU Inc. (OTCQB: ULUR) today provided an update on recent Altrazeal® developments. The international marketing network for Altrazeal® has been expanded through the appointment of exclusive licensees for 17 Middle East and North African markets.
Read More

09/30/2014

Addison, Texas, September 30, 2014; ULURU Inc. (OTCQB: ULUR), today announced the expansion of the Altrazeal® international marketing network. An agreement has been signed granting the exclusive marketing and distribution rights for Altrazeal® in Germany.
Read More

08/12/2014

Addison, Texas, August 12, 2014; ULURU Inc. (OTCQB: ULUR), today provided an update on its recent Altrazeal® commercial activities. In the past 45 days, shipments to fulfil orders have been made to the United Arab Emirates and Romania. Also, additional shipments have been made to Italy and Afghanistan to fulfil their initial orders.
Read More

07/08/2014

Addison, Texas, July 8, 2014; ULURU Inc. (OTCQB: ULUR) today announced that it has completed shipments to Serbia, Macedonia, Montenegro and Afghanistan. In addition, the international marketing network has been expanded to include Russia, Greece and the United Arab Emirates.
Read More

05/27/2014

Addison, Texas, May 27, 2014; ULURU Inc. (OTCQB: ULUR), today announced it has completed the further shipments of Altrazeal® for the Italian, Spanish and Portuguese markets.
Read More

05/21/2014

Addison, Texas, May 21, 2014; ULURU Inc. (OTCQB: ULUR) today announced details of the recent Altrazeal AG participation at the European Wound Management Association Conference that was held in Madrid on May 14-16, 2014.
Read More

04/07/2014

Addison, Texas, April 7, 2014; ULURU Inc. (OTCQB: ULUR), is pleased to provide an update on the pharmacoeconomic analysis being conducted in Europe on Altrazeal®, the Company’s innovative wound dressing. The purpose of this pharmacoeconomic analysis is to evaluate both the cost and healing benefits of Altrazeal® when compared to conventional dressings and advanced moist wound healing products.
Read More

02/26/2014

Addison, Texas, February 26, 2014; ULURU Inc. (OTCQB: ULUR), today provided an update on its business activities. The network of international exclusive marketing and distribution partners has been extended in Europe, the Middle East, Asia and the Caribbean.
Read More

12/18/2013

Addison, Texas, December 18, 2013; ULURU Inc. (OTCQB: ULUR), today announced a further expansion of the Altrazeal® international marketing and distribution network. An agreement has been signed granting the exclusive marketing and distribution rights for Altrazeal® in India.
Read More

12/11/2013

Addison, Texas, December 11, 2013; ULURU Inc. (OTCQB: ULUR), today announced the expansion of the Altrazeal® international marketing network. Agreements have been signed granting theexclusive marketing and distribution rights for Altrazeal® in Italy, Spain and Greece.
Read More

09/30/2013

Addison, Texas, September 30, 2013; ULURU Inc. (OTCQB: ULUR), today announced the expansion of the Altrazeal® international marketing network to include Scandinavia and Finland. Read More

09/05/2013

Addison, Texas, September 5, 2013; ULURU Inc. (OTCQB: ULUR), today announced that it has extended the territory for the International License for Altrazeal®, to include Africa (markets not already licensed), Latin America, the Commonwealth of Independent States, Georgia, Ukraine and Turkmenistan. Read More

08/26/2013

Addison, Texas, August 26, 2013; ULURU Inc. (OTCQB: ULUR), today announced the publication in the International Wound Journal of an article titled, “A prospective, randomized study of a novel transforming methacrylate dressing compared with a silver-containing sodium carboxymethylcellulose dressing on partial-thickness skin graft donor sites in burn patients”. Read More

07/08/2013

Addison, Texas, July 8, 2013; ULURU Inc. (OTCQB: ULUR) today announced the expansion of the Altrazeal® international marketing network to include South Africa, Czech, Slovakia and Portugal. Read More

05/31/2013

Addison, Texas, May 31, 2013; ULURU Inc. (OTCQB: ULUR) today announced an Altrazeal® expert meeting was held during the European Wound Management Association Conference held in Copenhagen on May 15-17, 2013. Read More

05/28/2013

Addison, Texas, May 28, 2013; ULURU Inc. (OTCQB: ULUR) today announced the publication, in the International Journal of Molecular Sciences, of an article, titled, “Bacterial Growth Kinetics Under a Novel Flexible Methacrylate Dressing Serving as a Drug Delivery Vehicle for Antiseptics.” Read More

01/14/2013

Addison, Texas, January 14, 2013; ULURU Inc. (OTCQB: ULUR) announced today the availability in the U.S. market of Altrazeal® in an innovative 0.75 gram blister pack. Read More

01/08/2013

Addison, Texas, January 8, 2013; ULURU Inc. (OTCQB: ULUR) announced today the first shipment of the 0.75 gram blister pack to our Austrian marketing partner. Read More

11/05/2012

Addison, Texas, November 5, 2012; ULURU Inc. (“ULURU”) (OTCQB: ULUR), announced today that the first shipment of Derazil™, the veterinary form of Altrazeal®, has been shipped to its partner company. Read More

10/31/2012

Addison, Texas, October 31, 2012; ULURU Inc. (“ULURU”) (OTCQB: ULUR), announced today that the initial production of the Altrazeal® 0.75 gram blister pack has been completed and this product has been received in Australia. Read More

09/20/2012

Addison, Texas, September 20, 2012; ULURU Inc. (OTCQB: ULUR), announced today the receipt of the first European order for the launch of Altrazeal® in Austria. Read More

07/31/2012

Addison, Texas, July 31, 2012; ULURU Inc. (OTCQB: ULUR), announced today that the first shipment of Altrazeal® has been received by our marketing partner in Australia. Read More

05/03/2012

Addison, Texas, May 3, 2012; ULURU Inc. (OTCQB: ULUR) today provided an update on the worldwide clinical and commercial activities for Altrazeal. Read More

03/20/2012

Addison, Texas, March 20, 2012; ULURU Inc. (NYSE Amex: ULU), announced today that Altrazeal® has been approved for marketing in New Zealand. Read More

02/23/2012

Addison, Texas, February 23, 2012; ULURU Inc. (NYSE AMEX: ULU), announced today that an Australian Register of Therapeutic Goods Certificate has been issued by the Therapeutic Goods Administration approving the marketing of Altrazeal® in Australia. Read More

01/17/2012

Addison, Texas, January 17, 2012; ULURU Inc. (NYSE AMEX: ULU), announced today that the License Agreement with Melmed Holdings AG for the marketing of Altrazeal® in Europe, Australia, New Zealand, the Middle East and Northern Africa has been finalized. Read More

01/17/2012

Addison, Texas, January 17, 2012; ULURU Inc. (NYSE AMEX: ULU), announced today that it has extended the previously announced European license for Altrazeal® to include the Middle East and North Africa. Read More

12/12/2011

Addison, Texas, December 12, 2011; ULURU Inc. (NYSE AMEX: ULU), announced today that it has extended the territory of the previously announced European license for Altrazeal®, with a subsidiary of Melmed Holdings AG, to include Australia and New Zealand. Read More

10/27/2011

Addison, Texas, October 27, 2011; ULURU Inc. (NYSE AMEX: ULU), today announced that additional data supporting the use of Altrazeal® in the treatment of Wagner Grade 2 diabetic foot ulcers was presented at a recent medical conference. Read More

10/13/2011

Addison, Texas, October 13, 2011; ULURU Inc. (NYSE AMEX: ULU), announced today that it has signed a binding letter of intent with Melmed Holdings AG, a company based in Switzerland, to license Altrazeal® for the European Union. Read More

05/04/2011

Addison, Texas, May 4, 2011; ULURU Inc. (NYSE AMEX: ULU) announced today that it has filed a 510(k) application with the U.S. Food and Drug Administration to obtain marketing authorization for Altrazeal® Collagen. Read More

04/14/2011

Addison, Texas, April 14, 2011; ULURU Inc. (NYSE Amex: ULU) announced today that the Company will have a commercial exhibit and present scientific data at the Symposium on Advances in Skin and Wound Care and Wound Healing Society (“SAWC/WHS”) which will be held on April 14 – 17, 2011 in Dallas, TX. Read More

03/23/2011

Addison, Texas, March 23, 2011; ULURU Inc. (NYSE AMEX: ULU) announced today that it has been issued U.S. Patent 7,910,135 - Hydrogel Wound Dressing and Biomaterials Formed In Situ and Their Uses. This patent provides additional coverage for Altrazeal® and, including The Patent Term Adjustment granted by the U.S. Patent and Trademark Office, extends patent coverage on Altrazeal® until January 2029. Read More

01/19/2011

Addison, Texas, January 19, 2010; ULURU Inc. (NYSE Alternext: ULU) announced today that it has signed a Binding Letter of Intent ("Agreement") with Exciton Technologies Inc. ("Exciton") to develop and market a product that will combine Altrazeal® with Exciton's proprietary exSALT™ Antimicrobial Technology. Read More

11/10/2010

Addison, Texas, November 10, 2010; ULURU Inc. (NYSE Amex: ULU) today provided a clinical update and summary of recent participation at major wound care conferences. Read More

11/08/2010

Addison, Texas, November 8, 2010; ULURU Inc. (NYSE Amex: ULU) today provided an update on its international commercial activities. Read More

09/30/2010

Addison, Texas, September 30, 2010; ULURU Inc. (NYSE Amex: ULU) announced today that the Company will have an extensive presence at the Clinical Symposium on Advances in Skin and Wound Care (“CSAWC”) which will be held on September 30 – October 3, 2010 in Orlando, Florida. Read More

08/02/2010

Addison, Texas, August 2, 2010; ULURU Inc. (NYSE Amex: ULU) announced today that Altrazeal® Transforming Powder Dressing has been granted CE Mark Certification in all countries within the European Economic Area (“EEA”). Read More

06/14/2010

Addison, Texas, June 14, 2010; ULURU Inc. (NYSE Alternext: ULU) announced today that six posters detailing clinical experience using Altrazeal™ Transforming Powder Dressing will be presented at the 2010 Joint Conference of the Wound Ostomy and Continence Nurses Society (WOCN) and World Council of Enterostomal Therapists (WCET) on June 14-16 in Phoenix, Arizona. ULURU will be present at the conference with an exhibit booth to provide education on best clinical practice with Altrazeal™ to the more than 4,500 nurse professionals attending the joint meeting who are experts in the care of patients with wound, ostomy and continence disorders. Read More

06/03/2010

Addison, Texas, June 3, 2010; ULURU Inc. (NYSE Alternext: ULU) announced today that advanced applications of the Nanoflex™ technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention. Read More

04/15/2010

Addison, Texas, April 15, 2010; ULURU Inc. (NYSE Amex: ULU) announced today that the company will present clinical evidence at the 2010 joint annual meeting of the Symposium on Advanced Wound Care and the Wound Healing Society (SAWC/WHS) in Orlando, Florida, April 17-20. SAWC/WHS is the premier wound care educational program within this clinical field and is the largest annual gathering of wound care clinicians in the United States. More than 2,000 physicians, podiatrists, nurses, therapists, and researchers are expected to attend the 2010 SAWC/WHS meeting. In addition to the presentation of the clinical evidence, the Company will also be providing educational guidance, showcasing advanced research on Altrazeal™ and products in the Altrazeal™ pipeline. Read More

04/08/2010

Addison, Texas, April 8, 2010; ULURU Inc. (NYSE Amex: ULU) announced today that the Company will be presenting clinical data at the 2010 American Professional Wound Care Association (APWCA) National Conference in Philadelphia, PA April 8-11, 2010. At the conference, Altrazeal™ clinical evidence, best clinical practices, and advanced clinical applications will be showcased in both podium and poster presentations. Read More

03/23/2010

Addison, Texas, March 23, 2010; ULURU Inc. (NYSE Amex: ULU) announced that it sponsored a Wound Dressing Workshop at the 2010 Diabetic Foot Global Conference. Attendees of the Diabetic Foot Global Conference (DFCon) in Hollywood, California on March 20, 2010 participated in a hands-on workshop where they were trained in “best clinical practice” for Altrazeal™. Participants learned application techniques, clinical endpoints, and methods for treating different wound types including diabetic foot ulcers, venous stasis ulcers and pressure ulcers. The workshop was led by Dr. John Steinberg, DPM of Georgetown University Hospital. Read More

01/21/2010

Dallas, Texas, January 21, 2010; ULURU Inc. (NYSE Alternext: ULU) announced today that it will make a presentation at a forum highlighting the business of nanomedicine at the Institute for Innovation & Entrepreneurship (University of Texas, Dallas). Conference details and the program can be found at innovation.utdallas.edu. Read More

12/09/2009

Addison, Texas, December 9, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today that a presentation on Altrazeal™ Transforming Powder Dressing will be made at the prestigious 10th Annual Wound Healing Science and Industry Conference to be held December 10-13, 2009 in St. Thomas, U.S. Virgin Islands. The presentation will include research on advanced applications of Altrazeal™ related to the development of future products in drug delivery and tissue engineering. This conference is organized as a collaborative series of symposia and poster presentations with many of the top scientists and clinicians in the field of wound care discussing advanced research and treatments. Conference details and the program can be found at www.stthomaswoundhealing.com. Read More

12/03/2009

Addison, Texas, December 3, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today that McKesson Medical-Surgical, Inc., one of the major pharmaceutical distributors in the United States, has approved ULURU Inc. to be one of its suppliers and has placed its first significant order for Altrazeal™. McKesson Medical-Surgical delivers a comprehensive offering of medical-surgical supplies, medical equipment and health care technology-related services to the alternate site market, including physician offices, surgery centers, long-term care facilities and home care businesses throughout the United States. Read More

10/22/2009

Addison, Texas, October 22, 2009; ULURU Inc. (NYSE Alternext: ULU) today announced that a poster highlighting the benefits of using Altrazeal™ in the home care market segment will be among the Altrazeal™ posters being presented at the 24th Annual "Clinical Symposium on Advances in Skin and Wound Care" in San Antonio, Texas from October 22-25. Read More

10/21/2009

Addison, Texas, October 21, 2009; ULURU Inc. (NYSE Alternext: ULU) today announced that there will be 16 poster presentations featuring clinical and pharmacoeconomic results at the 24th Annual “Clinical Symposium on Advances in Skin and Wound Care” to be held in San Antonio, Texas from October 22-25. Read More

09/16/2009

Addison, Texas, September 16, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal™ or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing. Read More

07/29/2009

Addison, Texas, July 29, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today that the application of Altrazeal™ and best clinical practice will be demonstrated in a hands-on Wound Care Pre Conference Workshop at the APMA Annual Scientific Meeting July 28 - August 2. In addition, clinical evidence on the treatment of wounds using Altrazeal™ Transforming Powder Dressing will be presented on posters during the meeting. Read More

05/05/2009

Addison, Texas, May 5, 2009; ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence utilizing Altrazeal™ Nanoflex Transforming Powder Dressing has been published in the respected peer-reviewed publication, International Wound Journal. The article, which is the first peer-review publication detailing clinical experience using Altrazeal™, was authored by a team of clinicians and scientists working at Southern Arizona Limb Salvage Alliance (“SALSA”) at the University of Arizona College of Medicine, located in Tucson, Arizona. Read More

04/23/2009

Addison, Texas, April 23, 2009; ULURU Inc. (NYSE AMEX: ULU) announced today that clinical evidence on the treatment of wounds using Altrazeal™ along with pre-clinical and physical data on Altrazeal™ and Altrazeal™ Silver will be presented at the annual Society for Advance Wound Care Conference (“SAWC”) being held in Grapevine, Texas, April 26-30, 2009. The clinical evidence and data will be presented on posters on display during the meeting. Read More

04/01/2009

Addison, Texas, April 1, 2009; ULURU Inc. (NYSE Alternext: ULU) announced today that clinical evidence on the treatment of wounds using Altrazeal™ Transforming Powder Dressing, and data on the physical properties of Altrazeal™ Silver will be presented at the annual APWCA National Clinical Conference in Philadelphia, April 2-5, 2009. The work will be presented in podium presentations and with posters on display during the meeting. Read More

03/13/2009

Addison, Texas, March 13, 2009; ULURU Inc. (NYSE Alternext: ULU) today announced the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Chairman of the Company’s Scientific Advisory Board. Currently, Dr. Jeffrey Niezgoda is the Medical Director of The Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. Luke's Medical Center, Aurora Health Care, in Milwaukee, Wisconsin. Read More

03/13/2009

Addison, Texas, March 13, 2009; ULURU Inc. (NYSE Alternext: ULU) announced that clinical evidence on the treatment of diabetic foot ulcers, and data on the use of its patented Nanoflex™ Technology for Therapeutic Delivery will be presented at the annual DFCon Global Meeting in Los Angeles, California March 19-21. The work will be presented on posters that will be on display during the meeting. Read More

11/04/2008

Addison, Texas, November 4, 2008; ULURU Inc. (NYSE Alternext: ULU) today announced that it has launched a new Altrazeal™ website designed to provide information to both health care professionals and patients on the clinical benefits of Altrazeal™. Read More

10/30/2008

Las Vegas, NV, October 30, 2008; ULURU Inc. (NYSE Alternext: ULU) – Clinical updates and new case studies on the application of Altrazeal™ - Transforming Powder Dressing were presented yesterday at a special session of this year's annual Clinical Symposium on Advances in Skin & Wound Care. The session was hosted by ULURU Inc. Read More

10/28/2008

Addison, Texas, October 28, 2008; ULURU Inc. (NYSE Alternext: ULU) today announced that it will present two posters at the “Clinical Symposium on Advances in Skin and Wound Care” being held in Las Vegas from October 27 to October 30, 2008. Learn More

10/21/2008

Addison, Texas, October 21, 2008; ULURU Inc. (NYSE Alternext: ULU) today announced that it has commenced a clinical study to evaluate patients with graft donor sites treated with ALTRAZEAL Silver compared with a market leading silver containing carboxymethylcellulose dressing. The study will be conducted at four clinical sites with 40 evaluable patients being enrolled. The first study site has been initiated and the Company plans to initiate additional sites within the next 30-days. Read More